(917) 310-3371
Simtriyo (centanafadine) was FDA-approved for ADHD on July 24, 2026, but it is not commercially available as checked October 12, 2026. Discuss current ADHD treatment while the manufacturer completes DEA scheduling and launch arrangements.
For help, call (917) 310-3371.
As checked October 8, 2026, the manufacturer reports FDA approval while DEA scheduling review continues and says Simtriyo is not commercially available. Confirm any future launch date, pharmacy supply, price and prescribing arrangements before planning a start. Discuss established ADHD options and current continuity needs with the responsible clinician. Do not stop an existing plan while waiting or treat forum experience as comparative evidence. Check the current manufacturer status before expecting access, and ask the prescriber how any future treatment change would be assessed.
Simtriyo is the brand name for centanafadine extended-release capsules. Otsuka announced FDA approval for ADHD on July 24, 2026. As checked October 8, the manufacturer still says DEA scheduling review is underway and the medicine is not commercially available. Approval and pharmacy supply are separate questions. Discuss current ADHD care with the responsible clinician while continuing your established plan. Confirm prescribing requirements and supply before considering a future Simtriyo start.
The announced indication includes adults and pediatric patients aged six and older weighing at least 20 kg. The label does not recommend use below those limits. Any future prescription needs a diagnosis and review of health history, previous response, interactions and current prescribing requirements. Children need an age-appropriate clinician for assessment and monitoring. FDA approval alone does not make the medicine available or provide a prescription.
Use the current manufacturer and regulatory information. A development announcement, approval, scheduling decision and pharmacy supply are different events.
Bring diagnostic and treatment records, the current regimen, side effects and practical goals. Discuss available established options with the responsible clinician.
If access changes, reassess the final requirements, suitability, medicine interactions and monitoring. Do not substitute or combine treatments based on a future brand announcement.
For a current ADHD review, bring childhood and adult assessment records, medicines and doses, pharmacy details, relevant medical history and your goals. Describe supply concerns early. If a new medicine becomes available, ask how the evaluation, pharmacy and benefit process would work. A previous prescription does not automatically establish continuation or suitability for a new product.
The linked label has boxed warnings for suicidal thoughts and behaviours in pediatric patients and for abuse, misuse and addiction. It also requires review of heart health, blood pressure, psychiatric risks and interactions. A CNS-stimulant classification must not be described as a risk-free nonstimulant option. Do not obtain an unofficial product or change medicines yourself while commercial access is pending. Severe chest symptoms, dangerous agitation or an immediate safety threat needs emergency care.
Continue the agreed existing ADHD plan unless the responsible prescriber changes it. Discuss benefit, daily function and adverse effects at the planned reviews. A status update does not authorize a refill or a switch. If supply problems affect current treatment, ask that prescriber for advice. Do not rely on a predicted launch or a patient forum to decide when another medicine stops.
As of October 8, the manufacturer reports no commercial supply while DEA scheduling review continues. Before any future start, confirm the price, payer benefits, pharmacy supply and prescribing arrangements. Ask separately about any research-study eligibility rather than assuming trial access. Ask about the actual assessment and continuing care available now. Check current scheduling and commercial access before expecting the medicine to be supplied. A prescription requires the responsible clinician’s assessment and authorization.
Simtriyo is the brand name for centanafadine extended-release capsules. Otsuka announced FDA approval for ADHD on July 24, 2026. As of October 8, 2026, the manufacturer described pending DEA scheduling and no commercial availability. Approval and pharmacy supply are separate questions. Discuss current ADHD care with the responsible clinician while continuing your established plan. Confirm prescribing requirements and supply before considering a future Simtriyo start.
The announced indication includes adults and pediatric patients aged six and older weighing at least 20 kg. The label does not recommend use below those limits. Any future prescription needs a diagnosis and review of health history, previous response, interactions and current prescribing requirements. Children need an age-appropriate clinician for assessment and monitoring. FDA approval alone does not make the medicine available or provide a prescription.
Ask Nao intake whether it participates in a currently recruiting study for this exact medicine. Search the official ClinicalTrials.gov record for the exact intervention, recruiting status, eligibility and listed study-site contact. Contact that research site directly. A manufacturer announcement or a routine Nao appointment does not enroll you, and investigational treatment should not replace an established care plan without clinical review.
The manufacturer’s October 8 statement says it is not yet commercially available while DEA scheduling review continues. FDA approval does not establish a supply.
Do not treat Simtriyo's use of a different mechanism as proof that it is noncontrolled. As of October 8, 2026, Otsuka described pending DEA scheduling and no commercial availability. FDA approval and controlled-substance classification are separate steps. Confirm the final status, supply and prescribing requirements with the clinician and manufacturer before making a treatment plan.
Bring the current medicine list, previous diagnosis and treatment reports, pharmacy history and any requested records. Prepare examples of childhood and adult difficulties and how they affect daily life. Explain sleep, caffeine, alcohol, substance use and mood changes. For telehealth, confirm the location where you will attend, privacy and any requested measurements before the visit.
Ask whether the service is screening, diagnostic evaluation, medication follow-up or formal psychological testing. These are different services. Bring prior assessments, medicine history and concrete examples from work, home and earlier life.
Review medicine and nonmedicine options, prior benefit, side effects and medical history. The clinician decides which physical measurements or other checks are needed. A stimulant decision includes misuse and substance-use risk assessment and continuing monitoring.
Set functional goals such as completing tasks, managing appointments or reducing impulsive interruptions. Confirm review timing, refill procedures and who will communicate with the pharmacy. A previous prescription does not automatically determine a new clinician’s decision.
Ask the selected service for the next available appointment for an ADHD evaluation. Confirm whether booking or a walk-in visit is appropriate before traveling. Simtriyo is not commercially available as checked October 12, 2026. The clinician can discuss currently available ADHD treatment; no prescription is guaranteed.
No. Personal accounts do not establish your response or a reliable comparison with another medicine. Clinical suitability needs individual assessment.
Centanafadine inhibits norepinephrine, dopamine and serotonin reuptake. Its label identifies it as a central nervous system stimulant. The mechanism does not establish that it is free of stimulant risks or better than another treatment for you. Trial results and personal accounts cannot substitute for an individual review or a direct comparison. A claim that a new mechanism eliminates anxiety, misuse or adverse effects is unsupported.
The manufacturer states that DEA scheduling review for Simtriyo (centanafadine) is pending. Do not infer a finalized federal controlled-substance schedule from an older description or from the label’s CNS-stimulant classification. Confirm the current prescribing information and scheduling status with the prescriber or pharmacist before making an access plan.
